Expand CVKD Menu
CVKD MENU

CVKD Latest Press Releases

-- January 12, 2026 --

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor Globe Newswire 8:00 AM

-- December 30, 2025 --

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System ACCESS Newswire 8:00 AM

-- December 29, 2025 --

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On ACCESS Newswire 8:00 AM

-- December 17, 2025 --

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 Globe Newswire 9:00 AM

-- December 12, 2025 --

Cadrenal's Quiet Expansion Play Is Starting to Get Loud ACCESS Newswire 11:00 AM
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market ACCESS Newswire 9:45 AM

-- December 11, 2025 --

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) Globe Newswire 8:05 AM

-- December 1, 2025 --

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors Globe Newswire 9:00 AM

-- November 19, 2025 --

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award Globe Newswire 8:00 AM

-- November 10, 2025 --

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 9:00 AM

-- September 29, 2025 --

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 Globe Newswire 4:30 PM

-- September 15, 2025 --

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes